Market capitalization | $7.53b |
Enterprise Value | $6.64b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 86.50 |
P/S ratio (TTM) P/S ratio | 98.01 |
P/B ratio (TTM) P/B ratio | 9.69 |
Revenue (TTM) Revenue | $76.81m |
EBIT (operating result TTM) EBIT | $-548.05m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
17 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:
17 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 77 77 |
-
|
|
Gross Profit | 73 73 |
14,443%
14,443%
|
|
EBITDA | -547 -547 |
57%
57%
|
EBIT (Operating Income) EBIT | -548 -548 |
57%
57%
|
Net Profit | -519 -519 |
49%
49%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Head office | United States |
CEO | William Sibold |
Employees | 376 |
Founded | 2011 |
Website | www.madrigalpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.